University of Alabama At Birmingham Comprehensive Cancer Center — Birmingham, Alabama

Public research footprint of University of Alabama At Birmingham Comprehensive Cancer Center, compiled from the ClinicalTrials.gov public registry.

161

Registered studies

Active

Recruiting now

133

Completed

Stopped or withdrawn

Most-studied conditions

Head and Neck Cancer · EBV-Related Non-Hodgkin Lymphoma · Lung Cancer · Lymphoma

Recently updated registry entries

NCT05488314 — A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic… (Active Not Recruiting)
NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… (Recruiting)
NCT02945800 — Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (Completed)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at University of Alabama At Birmingham Comprehensive Cancer Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.